Adherex Technologies Q1 Earnings Call Highlights

2 days ago 11

MarketBeat

Thu, May 14, 2026 astatine 10:06 AM CDT 7 min read

Key Points

Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercialized momentum for PEDMARK, reporting higher first-quarter sales, affirmative operating currency travel and aboriginal signs that caller income unit investments are expanding demand.

On the company’s first-quarter 2026 net call, Chief Executive Officer Jeffrey S. Hackman called 2026 “a defining period” for Fennec, citing advancement successful commercialized execution, objective involvement successful PEDMARK and the company’s fiscal position. PEDMARK is approved for pediatric patients 1 period of property and older with localized, non-metastatic coagulated tumors to trim the hazard of cisplatin-induced ototoxicity, oregon imperishable proceeding loss.

→ Rocket Lab Just Hit a New All-Time High—Time to Buy oregon Let It Breathe?

Chief Financial Officer Robert Andrade said nett merchandise income totaled $15.1 cardinal successful the archetypal quarter, compared with $8.8 cardinal successful the prior-year period, an summation of astir 73%. Andrade said the 4th marked the sixth consecutive 4th of nett merchandise income maturation since caller commercialized enactment took over.

Sales Force Expansion Drives Broader Reach

Chief Commercial Officer Terry Evans, participating successful his archetypal Fennec net call, said the company’s first-quarter show reflected benefits from “key strategical enhancements” made crossed the commercialized organization. In precocious 2025, Fennec launched an inaugural called Project Ignite, which included concern successful 14 caller territories and 4 frontline managers.

→ MP Materials Is Quietly Building a Rare Earth Powerhouse

Read Entire Article